AstraZeneca (LON:AZN) Rating Reiterated by Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Shore Capital in a note issued to investors on Monday, MarketBeat Ratings reports.

Several other equities research analysts have also commented on AZN. BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a report on Monday, February 12th. Barclays reiterated an “overweight” rating and set a £125 ($155.61) price objective on shares of AstraZeneca in a research note on Monday, April 8th. Jefferies Financial Group reiterated a “hold” rating and set a £110 ($136.94) price objective on shares of AstraZeneca in a research note on Friday, February 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a research note on Tuesday, March 12th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of £115.43 ($143.69).

AstraZeneca Trading Down 1.3 %

LON:AZN opened at £108.78 ($135.42) on Monday. AstraZeneca has a one year low of GBX 9,461 ($117.78) and a one year high of £123.92 ($154.26). The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. The firm has a market cap of £168.61 billion, a P/E ratio of 3,590.10, a P/E/G ratio of 0.89 and a beta of 0.19. The firm has a 50-day simple moving average of £103.42 and a 200-day simple moving average of £104.22.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.